You just read:

ViaCyte, Inc. Announces FDA Acceptance of IND to Commence Clinical Trial of VC-01™ Candidate Cell Replacement Therapy for Type 1 Diabetes

News provided by

ViaCyte

Aug 19, 2014, 09:00 ET